IFITM2 inhibitors are a specific class of chemical compounds that target and modulate the activity of the Interferon-Induced Transmembrane Protein 2 (IFITM2). IFITM2 is a member of the interferon-induced transmembrane (IFITM) family of proteins, which play a crucial role in the innate immune response to viral infections. These proteins are known for their ability to inhibit the entry of various enveloped viruses into host cells, thereby restricting viral replication and propagation. IFITM2, in particular, has been identified as a key player in this antiviral defense mechanism.
Chemical compounds classified as IFITM2 inhibitors are designed to interfere with the function of IFITM2 protein, often by binding to specific sites or regions within the protein. By doing so, these inhibitors reduce the inhibitory effect of IFITM2 on viral entry into host cells. This modulation of IFITM2 activity can be of significant interest in the context of virology research and understanding the mechanisms of viral infection. IFITM2 inhibitors primarily serve as valuable tools for scientific investigations into the molecular mechanisms governing viral entry and host-pathogen interactions. Researchers can utilize these compounds to probe the function of IFITM2 and its role in the host's immune response against viral infections, ultimately contributing to our broader understanding of virology and immune system dynamics.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat is a histone deacetylase inhibitor, potentially affecting gene expression, including possibly IFITM2, by altering chromatin structure. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is another histone deacetylase inhibitor, which may influence IFITM2 expression through epigenetic modifications. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine is a DNA methyltransferase inhibitor, potentially impacting IFITM2 expression by causing demethylation of its promoter region. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate is a histone deacetylase inhibitor with potential to alter gene expression, including IFITM2, by affecting chromatin accessibility. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid, a fatty acid with anticonvulsant properties, also acts as a histone deacetylase inhibitor, potentially influencing IFITM2 expression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can affect various cellular processes, potentially impacting IFITM2 expression through modulation of protein degradation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that may influence IFITM2 expression through its effects on cell signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an immunosuppressive agent that affects mTOR signaling, potentially influencing IFITM2 expression. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an epidermal growth factor receptor inhibitor, potentially affecting IFITM2 expression through modulation of cell signaling. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is another epidermal growth factor receptor inhibitor, with potential to influence IFITM2 expression through similar pathways as gefitinib. | ||||||